Condition: Prostate Cancer · Sponsor: Fabio Cury
It is a phase I study of radical hypofractionation delivering one single fraction of SBRT in patients with low- and favorable intermediate-risk prostate cancer that will undergo placement of the SpaceOAR hydrogel prior to treatment. Our hypothesis is that treatments can be safely delivered in one single fraction using SBRT provided the separation between the prostate and rectum is increased using the hydrogel
This description comes directly from the study's public registry record.
Marianna Perna · 514-934-1934 · marianna.perna@muhc.mcgill.ca
Tatiana Carvalho · 514-934-1934 · tatiana.carvalho@muhc.mcgill.ca
Always discuss trial participation with your own doctor first.
| McGill University Health Centre-Cedars Cancer Centre | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04004312